Sagimet Biosciences Announces Upsized $85 Million IPO

San Diego – July 18, 2023 – Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team advising the underwriters.

Sagimet offered 5,312,500 shares of Series A common stock at a public offering price of $16 per share, with a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Sagimet’s stock began trading on the Nasdaq Global Market on July 14, 2023, under the ticker symbol SGMT.

Goldman Sachs & Co., Cowen and Company and Piper Sandler & Co. acted as joint book-running managers for the offering, while JMP Securities acted as lead manager.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.